Ranolazine and Pulmonary Hypertension
The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart function, exercise capacity, chest pain and QOL have improved after 3 months of treatment with ranolazine. Ranolazine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension|
- Improve Angina Symptoms [ Time Frame: 3 months ] [ Designated as safety issue: No ]Assessed as average improvement in WHO Functional Class. The WHO Functional Class score ranges from 1 to 4, with higher scores indicating more impairment
- 6-Minute Walk Test [ Time Frame: 3 Months ] [ Designated as safety issue: No ]Improve Exercise Capacity measured by 6-Minute Walk Test
- Improve Quality of Life [ Time Frame: 3 Months ] [ Designated as safety issue: No ]The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The scores are averaged and transformed to a range of 0-100, in which higher scores reflect better health status and was performed at the conclusion of the study.
- RV Perfusion on Cardiac MRI [ Time Frame: 3 months ] [ Designated as safety issue: No ]The majority of patients did not undergo cardiac MRI because it was difficult for the patients to tolerate the imaging study. Therefore, we were not able to assess change in RV perfusion.
- Absolute RV Longitudinal Strain [ Time Frame: 3 months ] [ Designated as safety issue: No ]Change in absolute RV longitudinal strain as assessed by exercise stress echocardiography with speckle-tracking echocardiography at baseline and conclusion of the study
- Right Ventricular Hemodynamics [ Time Frame: 3 months ] [ Designated as safety issue: No ]Mean pulmonary artery pressure was assessed invasively by right heart catheterization at the conclusion of the study to estimate right ventricular hemodynamics.
|Study Start Date:||June 2010|
|Study Completion Date:||October 2014|
|Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
1000 mg PO BID
ranolazine 1000 mg PO BID for 3 months
Other Name: Ranexa
This study is looking to enroll patients with pulmonary hypertension (PH). PH is abnormally high blood pressure in the arteries of the lungs. It makes the right side of the heart need to work harder than normal and is usually caused by a narrowing of the small arteries of the lung. This narrowing makes it harder for the right side of the heart to circulate the blood to the lungs. Over time, the right side of the heart may become enlarged and symptoms (such as angina [chest pain] shortness of breath, fatigue, edema) begin to appear.
Ranolazine is a safe, well-tolerated, and FDA-approved medication for the treatment of chronic stable angina. Ranolazine may potentially improve blood flow to the right ventricle (RV), thereby relieving angina while simultaneously improving RV performance and contractility. This latter effect may increase stroke volume and cardiac output which could translate into benefits in exercise capacity and improved quality of life.
The purpose of this single center, non-randomized, prospective pilot study is to investigate the effects of 3 months treatment with ranolazine on pulmonary artery hemodynamics, exercise capacity and quality of life in patients with PAH and symptoms of angina or angina equivalent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01174173
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Sanjiv Shah, MD||Northwestern University|